NRX Pharmaceuticals (NRXP) Non Operating Income (2017 - 2026)
NRX Pharmaceuticals (NRXP) posted quarterly Non Operating Income of $3.3 million for Q1 2026, up 298.92% year-over-year from $830243.9 in Q1 2025, and down 33.55% quarter-over-quarter from $5.0 million in Q4 2025.
NRX Pharmaceuticals (NRXP) Non Operating Income (2017 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has reported Non Operating Income for 10 consecutive years, with $3.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Income rose 298.92% year-over-year to $3.3 million; the TTM figure through Mar 2026 stood at -$7.4 million (up 4.36% YoY), while the FY2025 annual figure was -$12.4 million, down 87.17% from the prior year.
- Non Operating Income eased to $3.3 million in Q1 2026 per NRXP's latest filing, from $5.0 million in the prior quarter.
- Across five years, Non Operating Income topped out at $5.0 million in Q4 2025 and bottomed at -$13.9 million in Q2 2025.
- Historically, Non Operating Income has averaged -$794352.9 across 5 years, with a median of -$353000.0 in 2022.
- Annual changes were most pronounced in 2022 — Non Operating Income jumped 1845.69% — and 2024, when it slumped 9081.08%.
- NRX Pharmaceuticals' Non Operating Income stood at -$353000.0 in 2022, then soared by 120.96% to $74000.0 in 2023, then plunged by 9081.08% to -$6.6 million in 2024, then jumped by 174.99% to $5.0 million in 2025, then plunged by 33.55% to $3.3 million in 2026.
- Business Quant data shows NRXP's Non Operating Income at $3.3 million in Q1 2026, $5.0 million in Q4 2025, and -$1.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | NRX Pharmaceuticals | 132.53 Mn | 105.83 Mn | 426,000.00 | -10.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.31 Mn |
| Dec 31, 2025 | 4.98 Mn |
| Sep 30, 2025 | -1.87 Mn |
| Jun 30, 2025 | -13.85 Mn |
| Mar 31, 2025 | -1.67 Mn |
| Dec 31, 2024 | -6.65 Mn |
| Sep 30, 2024 | 1.40 Mn |
| Jun 30, 2024 | -847,000.00 |
| Mar 31, 2024 | -530,000.00 |
| Dec 31, 2023 | 74,000.00 |
| Sep 30, 2023 | -254,000.00 |
| Jun 30, 2023 | -529,000.00 |
| Mar 31, 2023 | -1.67 Mn |
| Dec 31, 2022 | -353,000.00 |
| Sep 30, 2022 | 58,000.00 |
| Jun 30, 2022 | 2.62 Mn |
| Mar 31, 2022 | 2.26 Mn |
| Dec 31, 2021 | 22.57 Mn |
| Sep 30, 2021 | -16.95 Mn |
| Jun 30, 2021 | 17.00 Mn |